Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.

Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery.

Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success.

• 01:00 Meet Parashar Dhapola
• 05:45 AI in biopharma
• 09:29 AI automation vs. new capabilities
• 11:28 What makes single-cell omics data different
• 18:46 Risks of incorrect cell annotation
• 34:37 Future of single-cell analytics

This episode is produced with the support of Nygen Analytics. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• CyteType - AI powered cell type annotation
• Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure?
• The past, present, and future of genome sequencing